Equities researchers at StockNews.com began coverage on shares of Conformis (NASDAQ:CFMS – Get Rating) in a report issued on Friday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.
Separately, Oppenheimer lowered Conformis from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 9th.
Conformis Trading Down 8.9 %
Shares of CFMS stock opened at $1.23 on Friday. Conformis has a 12-month low of $1.05 and a 12-month high of $11.25. The company has a current ratio of 5.71, a quick ratio of 4.06 and a debt-to-equity ratio of 0.46. The stock’s 50-day moving average price is $1.46 and its 200-day moving average price is $2.20. The stock has a market capitalization of $9.23 million, a price-to-earnings ratio of -0.20 and a beta of 1.09.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the business. UBS Group AG boosted its position in shares of Conformis by 24.7% during the first quarter. UBS Group AG now owns 115,831 shares of the medical instruments supplier’s stock valued at $186,000 after buying an additional 22,911 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Conformis during the fourth quarter valued at approximately $91,000. Bank of New York Mellon Corp boosted its position in shares of Conformis by 2.3% during the third quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock valued at $71,000 after buying an additional 8,191 shares during the period. Renaissance Technologies LLC boosted its position in shares of Conformis by 4.1% during the third quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock valued at $911,000 after buying an additional 188,200 shares during the period. Finally, MYDA Advisors LLC purchased a new position in shares of Conformis during the third quarter valued at approximately $133,000.
Conformis Company Profile
ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.
- Get a free copy of the StockNews.com research report on Conformis (CFMS)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.